Gene therapy shot could replace monthly eye injections for wet AMD
NCT ID NCT04514653
First seen Nov 16, 2025 · Last updated May 21, 2026 · Updated 18 times
Summary
This study tests a gene therapy called RGX-314 as a potential one-time treatment for wet age-related macular degeneration (nAMD), a leading cause of vision loss. Currently, patients need frequent eye injections to control the disease. The trial involves about 146 adults aged 50-89 who have responded well to standard therapy. Participants receive one or two injections of RGX-314, and researchers compare their vision changes and safety against a standard treatment over up to 80 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
California Retina Consultants - Bakersfield /ID# 255910
Bakersfield, California, 93309-1677, United States
-
California Retina Consultants - Santa Barbara /ID# 255923
Santa Barbara, California, 93103, United States
-
Charles Retina Institute /ID# 255922
Germantown, Tennessee, 38138, United States
-
Duke University Medical Center /ID# 267646
Durham, North Carolina, 27710, United States
-
Eye Associates of New Mexico /ID# 255915
Albuquerque, New Mexico, 87109, United States
-
Johns Hopkins Hospital /ID# 255919
Baltimore, Maryland, 21287, United States
-
Mid Atlantic Retina /ID# 255906
Philadelphia, Pennsylvania, 19107, United States
-
Northern California Retina Vitreous Associates Medical Group, Inc /ID# 255920
Mountain View, California, 94040-4101, United States
-
Ophthalmic Consultants of Boston /ID# 255917
Boston, Massachusetts, 02114, United States
-
Retina Consultants - The Woodlands /ID# 255924
The Woodlands, Texas, 77384, United States
-
Retina Consultants of San Diego /ID# 255911
Poway, California, 92064-2530, United States
-
Retina Vitreous Assoc Med Grp /ID# 255921
Beverly Hills, California, 90211, United States
-
Retinal Diagnostic Center /ID# 272275
Campbell, California, 95008, United States
-
Retinal Research Institute /ID# 255925
Phoenix, Arizona, 85053, United States
-
Sierra Eye Associates /ID# 255908
Reno, Nevada, 89502, United States
-
Southeast Retina Center /ID# 255912
Augusta, Georgia, 30909, United States
-
Springfield Clinic - First /ID# 272274
Springfield, Illinois, 62702, United States
-
Tennessee Retina - Nashville /ID# 255918
Nashville, Tennessee, 37203-1513, United States
Conditions
Explore the condition pages connected to this study.